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in patients with schizophrenia. However, whether these changes reflect psychopathology, antipsychotic 
efficacy, or some other factor is not known. Our study aims to investigate the degree of oxidative stress in 
different BMI categories and to identify clinical symptomatology that may be paired with increased 
oxidative stress in a schizophrenia population. To this end, we performed a cross-sectional study and 
recruited 89 long-term inpatients with schizophrenia and collected the following variables: plasma 
malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), 
routine biochemical analysis, and psychopathology through the Positive and Negative Syndrome Scale 
(PANSS). The results indicate that the levels of the lipid peroxidation product, MDA, were significantly 
higher in the high BMI group than the low (normal) BMI group. As expected, high BMI was associated with 
an atherogenic lipid profile; however, it was also associated with fewer psychopathological symptoms. 
Multiple regression analysis found that MDA levels, the PANSS general psychopathology subscore, and 
triglyceride levels (all p < 0.05) were independent contributors to the BMI in patients. These results 
suggested that oxidative stress may play an important role in antipsychotic-induced weight gain. Further 
investigations using the longitudinal design in first-episode schizophrenia patients are needed to explore 
the beneficial effect of antioxidants on the abnormal lipid metabolism mediated by antipsychotic 
treatment. 
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Abstract
Antipsychotic pharmacotherapy is strongly obesogenic and is associated with increased oxidative stress in patients
with schizophrenia. However, whether these changes reflect psychopathology, antipsychotic efficacy, or some other
factor is not known. Our study aims to investigate the degree of oxidative stress in different BMI categories and to
identify clinical symptomatology that may be paired with increased oxidative stress in a schizophrenia population. To
this end, we performed a cross-sectional study and recruited 89 long-term inpatients with schizophrenia and collected
the following variables: plasma malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and glutathione
peroxidase (GPx), routine biochemical analysis, and psychopathology through the Positive and Negative Syndrome
Scale (PANSS). The results indicate that the levels of the lipid peroxidation product, MDA, were significantly higher in
the high BMI group than the low (normal) BMI group. As expected, high BMI was associated with an atherogenic lipid
profile; however, it was also associated with fewer psychopathological symptoms. Multiple regression analysis found
that MDA levels, the PANSS general psychopathology subscore, and triglyceride levels (all p < 0.05) were independent
contributors to the BMI in patients. These results suggested that oxidative stress may play an important role in
antipsychotic-induced weight gain. Further investigations using the longitudinal design in first-episode schizophrenia
patients are needed to explore the beneficial effect of antioxidants on the abnormal lipid metabolism mediated by
antipsychotic treatment.
Introduction
Weight gain is a common side effect of antipsychotics,
affecting 40–60% of schizophrenia patients1,2.
Antipsychotic-induced weight gain is a leading cause of
noncompliance, leading to increased risk for relapse3,4.
Moreover, obesity is also linked to greater morbidity,
mortality, and decreased life expectancy due to an
increased risk for cardiovascular and malignant
disorders5–8. Being obese can affect psychological well-
being, leading to lower quality of life9.
Oxidative stress occurs when there is an overproduction
of reactive oxygen species (ROS) or a deficiency of cellular
antioxidant defense mechanisms10,11. Accumulating evi-
dence suggests that increased oxidative stress may be
involved in the pathophysiology of schizophrenia12–14.
Several studies have shown oxidative stress in schizo-
phrenia, including disrupted activities of antioxidant
enzymes superoxide dismutase (SOD), catalase (CAT),
glutathione peroxidase (GPx), and glutathione (GSH)15–
18; increased lipid peroxidation products, thiobarbituric
acid reactive substances (TBARS), and malondialdehyde
(MDA)19–22; as well as decreased nonenzymatic anti-
oxidants in plasma, serum, red blood cells, and
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cerebrospinal fluid23,24. Preclinical and clinical studies
have suggested that both typical and atypical anti-
psychotic medications induce oxidative stress, particularly
with long-term antipsychotic treatment19,25–27.
Fat accumulation and obesity are linked to enhanced
oxidative stress28,29. Several studies have established the
correlation of biomarkers and end-products (such as lipid
peroxidation products) of free radical-mediated oxidative
stress with body mass index (BMI) as well as an inverse
relationship between BMI and biomarkers of an effective
antioxidant system30–32. It appears that ROS themselves
can act to increase adipogenesis, and alter the production
of adipocytokines28,33–35. Thus, it appears that there is an
intrinsic relationship between oxidative stress and obesity.
In view of the marked alterations of oxidative stress and
higher prevalence of obesity in schizophrenia patients and
the intrinsic relationship between oxidative stress and
obesity, it would be important to explore the association
between them in schizophrenia patients. However, to our
best knowledge, no study has investigated the alterations
of oxidative stress in different BMI groups of schizo-
phrenia patients. The goal of this study was to address this
gap through exploring the following: (1) whether the
plasma levels or activity of oxidative stress-related mar-
kers, including SOD, CAT, GPx, and MDA were altered in
different BMI groups of schizophrenia patients; (2) whe-
ther the differences of clinical symptoms and lipid profiles
were observed in different BMI groups of patients; (3)
whether there were relationships between oxidative stress,
obesity, and clinical symptoms in this population.
Materials and methods
Subjects
This is a cross-sectional study. Eighty-nine inpatients
with schizophrenia were recruited from Beijing Hui-
Long-Guan hospital, a Beijing-city owned psychiatric
hospital. All patients met the following inclusion criteria:
(1) age 35–65 years, Han Chinese; (2) confirmed DSM-IV
diagnosis of schizophrenia; (3) at least 5 years of illness;
and (4) stable doses of oral antipsychotic drugs for at least
12 months before enrollment. The average duration of
disease was 28.4 ± 8.4 years and average duration of cur-
rent antipsychotic treatment was 13.3 ± 8.4 years.
Since admission, all patients received dietetically
balanced hospital meals which were occasionally supple-
mented by gifts (usually fruit). Patients had the opportu-
nity to exercise for about an hour per day. Antipsychotic
drug treatment was mainly monotherapy, primarily clo-
zapine and risperidone.
A complete medical history, physical examination, and
laboratory tests were obtained from patients. Any subjects
with major medical illness were excluded. None of the
subjects met the criteria for drug or alcohol abuse or
dependence. All patients who received any
immunomodulators or antioxidants in the last 12 weeks
were excluded from the study. All subjects gave informed
consent to participate in the study, which was approved
by the Institutional Review Board of Beijing Hui-
LongGuan Hospital.
BMI measurements
Bodyweight and height were assessed in a standardized
fashion to calculate BMI (weight over squared height, kg/
m2). Height was measured to the nearest millimeter, with
the subjects barefooted and standing upright. Bodyweight
was measured with an electronic scale calibrated to ±
0.1 kg; subjects were weighed in light indoor clothing.
According to the Chinese Working Group on Obesity in
China (WGOC) criteria36, patients were defined as obese
with BMI ≥ 28 kg/m2 and overweight with 24 ≤ BMI < 28
kg/m2. Hence, our patients were classified as low BMI
group (BMI≤24 kg/m2) and high BMI group (BMI >
24 kg/m2).
Clinical measurements
The patients’ psychopathology was assessed using the
Positive and Negative Syndrome Scale (PANSS) by two
psychiatrists, who had simultaneously attended a training
session on using PANSS. Repeated assessments for the
PANSS total score maintained an inter-rater correlation
coefficient greater than 0.8.
Routine biochemical analysis
Venous blood from the forearm vein was collected
between 7 and 9 AM following an overnight fast. The
biochemical analysis was performed by a technician blind
to the clinical status of the subjects. The serum lipid
profiles, including triglycerides (TG), total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), and cholesterol
(CHO), apolipoprotein (ApoA1) and ApoB were mea-
sured in the hospital laboratory center using commercially
available kits from Leadman (Beijing Leadman Bio-
technology Co. Ltd., Beijing, China) and by an automatic
biochemistry analyzer AU2700 (Olympus, Japan).
Oxidative stress assessment
Blood samples from schizophrenia inpatients were col-
lected between 7 and 9 AM following an overnight fast.
The plasma was separated, aliquoted, and stored at
−70 °C before use. All antioxidant enzymes and lipid
peroxidation products in plasma were measured by a
technician, who was blind to the clinical status of subjects.
Determination of lipid peroxidation
Lipid peroxidation levels were monitored by determin-
ing the end product of lipid peroxidation MDA by the
thiobarbituric acid (TBA) method, which was modified
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from the method of Yagi37. Plasma MDA values were
calculated using the extinction coefficient of
MDA–thiobarbituric acid complex at 532 nm. MDA
results were expressed as nmol/ml.
SOD activity measurement
Determinations of plasma total SOD activities were
performed using a standard assay involving spectro-
photometric determination of the inhibition of
superoxide-induced formation of nitrite from hydro-
xylamine, as described by Oyanagui38. Xanthine–xanthine
oxidase provided the superoxide source. One unit is
defined as the amount of SOD that inhibits 50% of nitrite
formation under the assay conditions. Activity was
expressed as units per milliliter plasma (U/ml). The inter-
and intra-assay coefficient of variation for SOD activity
was 4.1% (n= 6) and 3.2% (n= 6), respectively.
GPx activity measurement
GPx activity was measured by a modification of the
method reported in previous study39. The enzymatic
reaction was initiated by adding H2O2 to the reaction
mixture containing reduced GSH, reduced nicotinamide
adenine dinucleotidephosphate (NADPH), and glu-
tathione reductase. The change in absorbance at 340 nm
was monitored by a spectrophotometer. One unit of GPx
is defined as micromoles of NADPH oxidized per minute.
Activity was given in units per liter plasma volume. The
intra- and inter-assay coefficient of variation was 4.8% (n
= 6) and 5.7% (n= 6), respectively.
CAT activity measurement
CAT activity was assayed by the method of Aebi40. This
method was based on the decomposition of hydrogen
peroxide by CAT. CAT catalyzes the transformation of
hydrogen peroxide to water and oxygen. CAT activity was
determined by monitoring the decreased absorbance
spectrophotometrically at 240 nm due to degradation of
hydrogen peroxide. One unit of CAT was defined as the
amount of enzyme that decomposes 1 μmol H2O2/min
under specific conditions. CAT activity is expressed as U/
ml. The intra- and inter-assay coefficient of variation was
4.5% (n= 6) and 5.9% (n= 6), respectively.
Statistical analysis
Demographic and clinical variables of different BMI
groups were compared using analysis of variance
(ANOVA) for continuous variables and chi-squared test
for categorical variables. Since the majority of the vari-
ables were normally distributed in different BMI groups
(Shapiro–Wilk test), the principal outcome analysis con-
sisted of analysis of variance for comparison between two
different BMI groups. When significance was found in
ANOVA, the effects of gender, age, education, duration of
illness, antipsychotic treatment (type, dose, and duration
of treatment), and the PANSS total and its subscale scores
were tested by adding these variables to the analysis
model as covariates. Relationships between variables were
assessed with Pearson’s product moment correlation
coefficients. Bonferroni corrections were applied to each
test to adjust for multiple testing. Multivariate regression
analysis (stepwise regression model) was used to assess
correlations of BMI and oxidative stress while adjusting
for various potentially confounding variables of gender,
age, education, duration of illness, antipsychotic treat-
ment (type, dose, and duration of treatment), and the
PANSS total and its subscale scores. SPSS version 16.0
was used to do all statistical analyses. Statistical sig-
nificance was defined as P < 0.05.
Results
Demographics
Demographic data and lipid profiles in the two BMI
groups are displayed in Table 1. There was no significant
difference in age, education, gender, duration of








F or χ2 df P-value
Age (years) 51.2 ± 6.8 52.1 ± 8.7 0.272 1,87 0.603
Education (years) 9.6 ± 2.5 9.8 ± 2.5 0.157 1,87 0.693
Male/female 26/8 34/21 2.054 1 0.171
Duration of illness
(years)
27.9 ± 8.7 28.3 ± 9.5 0.054 1,87 0.816
Age of onset (years) 23.6 ± 5.7 23.6 ± 6.2 0.000 1,87 0.989
Hospitalization
numbers
3.8 ± 1.9 4.0 ± 3.0 0.150 1,87 0.699
BMI (kg/m2) 21.1 ± 2.3 27.0 ± 2.2 144.9 1,87 0.000









12/22 10/45 3.306 1 0.081
TG 1.4 ± 0.7 1.9 ± 1.1 6.557 1,86 0.012
HDL-c 1.1 ± 0.1 1.1 ± 0.2 2.384 1,86 0.126
LDL-c 2.8 ± 0.6 3.1 ± 0.6 4.317 1,86 0.041
APOA 1.2 ± 0.1 1.2 ± 0.1 1.370 1,86 0.245
APOB 0.7 ± 0.1 0.8 ± 0.5 3.467 1,86 0.066
CHO 4.3 ± 0.8 4.6 ± 1.1 1.942 1,86 0.167
AP antipsychotic, CPZ chlorpromazine, BMI body mass index, TG triglycerides, TC
total cholesterol, HDL-c high-density lipoprotein cholesterol, LDL-c low-density
lipoprotein cholesterol, CHO cholesterol
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treatment, age of onset, hospitalization numbers, or daily
antipsychotic dose (chlorpromazine equivalent) and the
type of antipsychotic drugs between the two different BMI
groups (all P > 0.05). However, TG levels (F= 6.557, df=
1,86, P= 0.012) and LDL-c (F= 4.317, df= 1,86, P=
0.041) were significantly higher in the high BMI group
than the low BMI group. Moreover, correlation analysis
showed that BMI was positively correlated with TG (r=
0.438, P= 0.000) and LDL-c (r= 0.245, P= 0.021),
respectively.
MDA levels and antioxidant enzyme activities in different
BMI groups
Plasma MDA levels were significantly higher in the high
BMI group than the low BMI group (F= 7.472, df= 1,84,
P= 0.008). This difference remained significant after
covarying for gender, age, education, duration of illness,
and daily CPZ equivalent dose (P= 0.015). Correlation
analysis showed that MDA levels were positively asso-
ciated with BMI (r= 0.333, df= 1,84, P= 0.002) (Fig. 1).
However, levels of SOD, GPx, and CAT did not differ
between the two groups, indicating that this finding is
specific to MDA (Table 2).
Clinical symptoms in different BMI groups
As shown in Table 3, the PANSS total score (F= 6.232,
df= 1,84, P= 0.015), negative (F= 5.019, df= 1,84, P=
0.028) and general psychopathology subscore (F= 4.766,
df= 1,84, P= 0.032) were significantly lower in the high
BMI group than the low BMI group. The positive symp-
tom subscore did not significantly differ between groups
(P= 0.14). When gender, age, education, duration of ill-
ness, and daily CPZ equivalent dose were added as cov-
ariates, the differences in the PANSS total score, negative
and general psychopathology subscore remained
significant (all P < 0.05). Furthermore, due to an imbal-
anced number of the patients treated with clozapine
between the high and low BMI groups (85% vs. 65%), we
further did ANCOVA using the antipsychotic types (clo-
zapine vs. non-clozapine or clozapine vs. risperidone) as
covariates, still showing the significant differences in the
PANSS total score, negative and general psychopathology
subscore between the low and high BMI groups (all P <
0.05). Correlation analysis further showed that negative
psychopathology subscore was negatively associated with
BMI (r= –0.243, df= 1,84, P= 0.026).
Relationship between BMI, oxidative stress, clinical
symptoms, and lipid profiles
Using correlation analysis, we found that GPx activity
was negatively associated with TG (r= –0.299, P= 0.005)
and SOD activity was positively correlated with the
negative psychopathology subscore (r= 0.330, P= 0.002)
and the PANSS total score (r= 0.229, P= 0.037). Multiple
regression analysis showed that MDA levels (β= 0.245, t
= 2.490, and P= 0.015), the PANSS general psycho-
pathology subscale (β=−0.207, t=−2.129, and P=
0.037), and TG levels (β= 0.434, t= 4.433, and P= 0.000)
were independent contributors to the BMI after control-
ling for gender, age, education, duration of illness, and
daily CPZ equivalent dose.
Fig. 1 Correlation analysis showed that MDA levels were positively
associated with BMI
Table 2 Antioxidant enzymes and MDA levels in different
BMI groups
Variable Low BMI group High BMI group F df P-value
SOD 86.9 ± 18.8 82.9 ± 17.7 1.014 1,86 0.317
GPx 104.2 ± 30.2 100.9 ± 25.2 0.351 1,84 0.576
CAT 2.1 ± 1.5 1.6 ± 1.1 2.221 1,85 0.140
MDA 8.4 ± 5.0 12.6 ± 7.6 7.472 1,84 0.008
BMI body mass index, SOD superoxide dismutase, CAT catalase, GPx glutathione
peroxidase, MDA malondialdehyde








75.1 ± 17.8 66.4 ± 14.1 6.232 1,84 0.015
P subscore 16.7 ± 6.1 14.9 ± 5.3 2.202 1,84 0.142
N subscore 26.0 ± 6.0 23.3 ± 4.9 5.019 1,84 0.028
G subscore 35.6 ± 9.4 31.7 ± 7.1 4.766 1,84 0.032
PANSS positive and negative syndrome scale, P positive symptom, N negative
symptom, G general psychopathology syndrome
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Discussion
The major findings of the present study on schizo-
phrenia long-term inpatients are the following: (1) the
levels of the lipid peroxidation product MDA were sig-
nificantly higher in the high BMI group; (2) the high BMI
group showed fewer psychopathological symptoms and a
more atherogenic lipid profile; (3) BMI status, oxidative
stress, lipid profiles, and clinical symptoms were tightly
correlated.
We found that the lipid peroxidation product MDA
levels were significantly higher in the high BMI group and
that MDA levels positively associated with BMI. Also, we
found a negative association between GPx activity and TG
levels. Our results were consistent with previous studies
showing a close correlation between BMI and the bio-
markers and end-products of free radicals-mediated oxi-
dative stress31,32,41, as well as an inverse association
between obesity and antioxidant defense markers30. Pre-
vious studies showed a correlation of fat accumulation
with the overproduction of ROS28 and that obesity is
associated with excessive ROS production and activation
of the antioxidant defense system. This suggests that
metabolic disease may be an important contributor to
systemic oxidative stress35. Conversely, chronic elevation
in ROS has been found to promote insulin resistance and
adipogenesis, suppress adiponectin expression and
secretion, and upregulate the expression of proin-
flammatory cytokines (PAI-1, IL-6) and macrophage
chemoattractive molecule (MCP-1)28,42. It is possible that
increased ROS lead to dysfunction of lipid metabolic
pathways through direct lipid peroxidation35. Clinical
studies have also found decreased activities of SOD, GPX,
and CAT and increased lipid peroxidation products,
including MDA, lipid hydroperoxides, and conjugated
dienes in the plasma of obese subjects32,43–45, providing
evidence for this theory.
In schizophrenia, antipsychotic treatment induces obe-
sity and is associated with the alteration of oxidative stress
parameters19,25–27. It may be the case that primary oxi-
dative damage induced by antipsychotics then leads to the
development of obesity. However, this is only our spec-
ulation as the exact relationship between overweight/
obesity and enhanced oxidative stress in the chronic
schizophrenia patients warrants future investigation. In
either case, elevated ROS are independently associated
with poorer health outcome and should be addressed; use
of antioxidants such as EGB761 combined with anti-
psychotic drugs targeting may reduce oxidative stress and
potentially alleviate clinical symptomatology46,47, espe-
cially for those with higher BMI. Further investigations
are needed to elucidate the beneficial effect of anti-
oxidants on the outcome of schizophrenia, especially for
those obese schizophrenia patients.
Our study demonstrated that the high BMI group
experienced fewer psychopathological symptoms. The
results were consistent with previous studies showing that
antipsychotic-induced weight gain was associated with
improvement in psychopathology48,49. We also have pre-
viously demonstrated an inverse correlation between BMI
and PANSS total score in schizophrenia patients treated
with long-term clozapine50 and between BMI and the
PANSS negative symptom score in chronic and medicated
schizophrenia patients2. The improvement of the psy-
chopathology accompanied by weight gain may be a side
effect indicating antipsychotic medication efficacy48. It is
worthy of mentioning that the majority of the high BMI
group (85%) but the minority of the low BMI group (65%)
were treated with clozapine. Since clozapine was more
effective but caused more weight gain than risperidone, it
is likely that the patients on more clozapine showed
higher BMI and lower PANSS scores than those on ris-
peridone. However, after the ANCOVA test using the
antipsychotic types (clozapine vs. non-clozapine or clo-
zapine vs. risperidone) as covariates, the significant dif-
ferences in the PANSS scores still remained, suggesting
that the relationship between the lower PANSS scores and
high BMI group might not be due to the effects of the
antipsychotic medications. However, several other studies
reported that the weight gain or obesity was not sig-
nificantly associated with changes in symptoms in
response to antipsychotic treatment51,52. The possible
reasons for this difference may be related to some com-
plicating factors, such as type, dose, treatment duration,
medication adherence, clinical status, the baseline level of
psychopathology, reliability of assessment, and con-
comitant medications48,51.
We also demonstrated that SOD activity was positively
correlated with the negative psychopathology subscore
and the PANSS total score in chronic schizophrenia
patients. This result is consistent with work showing a
similar association in the first few weeks of antipsychotic
therapy26. Our own previous study also reported that
greater change in SOD was correlated with greater
symptom improvement during antipsychotic treatment27.
These results suggested that antioxidant enzyme SOD
activity might be associated with psychopathological
symptoms severity. However, Tsai et al. also reported the
seemingly contradictory result that PANSS total scores
were significantly negatively correlated with serum GPx
activity and GSH levels 26. The exact mechanisms
underlying the association between the psychopathologi-
cal symptoms and oxidative stress parameters are still
unclear.
We also demonstrated that the high BMI group had
higher atherogenic lipid profiles in chronic schizophrenia
patients which is entirely consistent with current medical
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knowledge on the relationship between obesity and dys-
lipidemia53–55.
Several limitations of the study should be noted here.
First, this was a cross-sectional study design and cannot
show direct causality between weight gain, altered oxi-
dative stress biomarkers, and clinical symptoms in schi-
zophrenia patients. Second, the sample consisted of long-
term inpatients, with more baseline-severe psycho-
pathology, longer duration of illness, treatment, different
medication history, and hospitalization than typical schi-
zophrenia patients. Measuring the variable reported in
this study in a longitudinal cohort design with first-
episode and medication-naive patients could clarify the
relationships between oxidative stress, weight gain, and
clinical responses. Third, previous studies have shown
that clozapine or risperidone treatment have different
antioxidant effects56,57. This fact is an important con-
founding factor of this study. Moreover, although all
patients received either risperidone or clozapine mono-
therapy when they were recruited, we did not collect the
data for the medications the patients had taken before
risperidone or clozapine. Thus, whether or how the
medication history may contribute to the alterations of
oxidative stress parameters in our current study is still
unknown. Therefore, it is important to take into account
the type of antipsychotic medications in the future study
of oxidative stress. Fourth, in this study, TBARS assay was
used to measure the plasma MDA values, which is an
imprecise and nonspecific measure of MDA58. One
alternative approach is to separate interfering substances
from MDA–TBA adduct by high-pressure liquid chro-
matography (HPLC) prior to spectrophotometric mea-
surement. This HPLC procedure provides considerably
better sensitivity and specificity, which results in more
reliable reference values than any previously published
results. Another limitation of our study is that we did not
assess smoking status, although smoking is highly pre-
valent in this patient population—over 75% as found in
our previous study59. This factor may affect weight gain,
oxidative status, and symptomatology. However, given
that nicotine is a well-known appetite suppressant and
appears to reduce negative symptomatology59, the corre-
lation would not be in the direction demonstrated in our
current work.
In conclusion, we have demonstrated that high BMI is
associated with the increased oxidative stress, higher
atherogenic lipid profiles, and lower psychopathological
symptoms in chronic schizophrenia patients. Due to the
cross-sectional design, we cannot demonstrate causality
between BMI, oxidative stress, and clinical psychopatho-
logical symptoms in our schizophrenia patients. However,
it appears that oxidative stress may play an important role
in antipsychotic-induced weight gain. Therefore, we
speculate that combining the antioxidants with
antipsychotic drugs may reduce oxidative stress and fur-
ther may reduce or prevent the antipsychotic-induced
weight gain in schizophrenia patients. Further investiga-
tions using the longitudinal design in first-episode schi-
zophrenia patients are needed to explore the beneficial
effect of antioxidants on the therapeutic outcome, as well
as on the abnormal lipid metabolism mediated by anti-
psychotic treatment.
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